Mmx Mesalamine/Mesalazine
Ulcerative Colitis
ShirePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
13 Active assets in the Ulcerative Colitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxygen Jay C. Buckey Jr. | Phase 4 | BB |
Mesalamine Shire | Phase 3 | B |
Hextend Corewell Health West | Phase 3 | B |
Gralise Shirley Ryan AbilityLab | Phase 4 | B |
Pembrolizumab Diwakar Davar | Phase 2 | B |
View all 30 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →